NCT00532025终止2 期
A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment Following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients Not Eligible for Cisplatin-based Adjuvant Chemotherapy
Johannes Gutenberg University Mainz3 个研究点 分布在 1 个国家目标入组 134 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 134
- 试验地点
- 3
- 主要终点
- Progression-free survival (PFS) clinical and radiological assessment of remission status (RECIST criteria)
研究概览
简要总结
This is an open-label, single-armed, multicentric, phase II study of Sorafenib treatment following surgery for NSCLC.
The primary hypothesis is to increase the progression-free survival (PFS) of the experimental group in comparison to a historical control group. For sample size calculation a 2 year PFS of 50% was calculated for the historical control group, and a 2 year PFS of 67% was estimated for the intervention group. These estimates are based on the actual PFS and overall survival (OS) of a defined population of 120 NSCLC patients treated at a single institution with surgery alone or surgery followed by adjuvant radiotherapy, which compares favorably to published international results, and the improvement of PFS achieved by 4 cycles of cisplatin/vinorelbine-based cytotoxic chemotherapy in published randomized trials.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed diagnosis of NSCLC pathological stages I, II or III A
- •Patients must have completely resected disease and may not be treated with prior chemotherapy. Patients must have fully recovered from surgery prior to initiation of study treatment.
- •Adjuvant radiotherapy for stage III A disease is permitted given that the patient has recovered from all radiation-induced toxicities. In those patients, a complete restaging will be performed prior to enrolment into the trial.
- •Patients with completely resected NSCLC stage II or III A, who for medical reasons are not eligible for adjuvant chemotherapy consisting of a standard regimen of 4 cycles cisplatin/vinorelbine
- •Patients with completely resected NSCLC stage II or III A, who are not willing to undergo adjuvant chemotherapy with 4 cycles of cisplatin/ vinorelbine, are also eligible.
- •Age ≥ 18 years
- •ECOG performance status ≤ 2
- •Normal organ and marrow function defined as:
- •Hematopoetic: absolute neutrophil count >1,500/mm3, platelet count > 100,000/mm3, hemoglobin > 9 g/dL INR < 1.5 ULN and PTT within normal limits Hepatic: total bilirubin < 1.5 x ULN, AST or ALT < 2.5 x ULN Renal: creatinine < 1.5 x ULN
- •Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
- •Women of childbearing potential and men must agree to use adequate birth contraception prior to study entry and for the duration of study participation. Women and men should use adequate birth control for at least 3 months after the last administration of Sorafenib.
- •Written informed consent
排除标准
- •Any other histology (e.g. SCLC, carcinoid tumors) or disease stages other than I to III A
- •Patients who are eligible and willing to undergo a standard adjuvant chemotherapy regimen (4 cycles of cisplatin/vinorelbine)
- •Any prior systemic anticancer therapy including chemotherapy, targeted agents, experimental therapy or biological therapy for NSCLC
- •Cardiac disease: congestive heart failure > class II NYHA, patients must not have unstable angina pectoris or new onset of angina pectoris or myocardial infarction within the past 6 months, or cardiac ventricular arrhythmias requiring antiarrhythmic therapy
- •Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal therapy
- •Known brain metastasis. Patients with symptoms should undergo CT scan/MRI of the brain to exclude brain metastasis
- •Active clinically serious infections > NCI-CTCAE Grade 2
- •Thrombotic or embolic events including transient ischemic attacks within the past 6 months
- •Hemorrhage/bleeding event ≥ NCI-CTCAE Grade 3 within 4 weeks before first dose of study drug
- •Serious non-healing wound, ulcer or bone fracture
- •Evidence or history of bleeding diathesis or coagulopathy
- •Therapeutic anticoagulation with Vitamin K antagonists such as warfarin, phenprocoumon, or with heparins or heparinoids. Low dose warfarin/phenprocoumon is permitted if INR is < 1.
- •Low dose aspirin (300 mg/d) is permitted.
- •Use of St John's Wort or rifampicin
- •Major surgery, open biopsy or significant traumatic injury within 4 weeks before first dose of study drug
- •Known or suspected allergy to Sorafenib or any agent given in the course of this trial
- •Previous cancer that is distinct in primary site or histology from NSCLC except cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors or any cancer curatively treated ≥ 3 years prior to study entry.
- •Substance abuse, medical or psychological condition that may interfere with the patient´s participation in the study
研究组 & 干预措施
1
Experimental
Sorafenib treatment
干预措施: Sorafenib (Drug)
结局指标
主要结局
Progression-free survival (PFS) clinical and radiological assessment of remission status (RECIST criteria)
时间窗: 2 years
次要结局
- Progression free survival(3 and 4 years)
- Assessment of safety and tolerability of Sorafenib when administered as adjuvant treatment following surgery for NSCLC(2, 3 and 4 years)
- Assessment of biomarkers relevant to Sorafenib response and disease state, and their correlation to clinical outcome(4 years)
- Overall survival(3 and 4 years)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsThyroid CarcinomaNCT02114658Bayer18
进行中（未招募）
1 期
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159
终止
2 期
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.Carcinoma, Renal CellNCT00678288Bayer16
已完成
2 期
Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated TumorsMetastatic Colorectal Cancer Patients With KRAS Mutated TumorsNCT01715441Institut du Cancer de Montpellier - Val d'Aurelle173
已完成
2 期
Sorafenib + mFOLFOX for Hepatocellular CarcinomaHepatocellular CancerNCT01775501Massachusetts General Hospital40